H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Agile Therapeutics (NASDAQ: AGRX) today and set a price target of $8. The company’s shares closed yesterday at $2.83.
Livnat said:
“FDA meeting minutes hopefully confirm Twirla is ready for resubmission then potential approval by beg-2019.”
According to TipRanks.com, Livnat is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -10.5% and a 29.4% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.
Currently, the analyst consensus on Agile Therapeutics is Strong Buy and the average price target is $6, representing an 112.0% upside.
In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $4 price target.
See today’s analyst top recommended stocks >>
Based on Agile Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $6.83 million. In comparison, last year the company had a GAAP net loss of $7.52 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agile Therapeutics, Inc. engages in the development and commercialization of new prescription contraceptive products. Its product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company was founded on December 22, 1997 and is headquartered in Princeton, NJ.
